FDA warns against illegal copycat drugs, Molina stock sinks

February 6, 2026 - 23:18

The U.S. Food and Drug Administration has issued a forceful warning, promising "swift action" against companies producing and distributing illegal copycat drugs. This announcement sent immediate ripples through the healthcare sector, impacting specific stocks during today's trading session.

The warning targets products that mimic legitimate prescription medications, including notable weight-loss drugs, but are unlawfully compounded or manufactured. The agency emphasized the significant health risks these unapproved versions pose to consumers, as they bypass the rigorous safety, efficacy, and quality standards required for FDA-approved medications.

On Wall Street, the news contributed to a sharp decline for telehealth company Hims & Hers Health. Investor concern over the broader regulatory crackdown on compounded drug alternatives drove the stock lower. In a separate development, Molina Healthcare shares plummeted dramatically, falling over 25% following the release of its quarterly earnings. The insurer's weak forward guidance, which fell significantly short of analyst expectations, was the primary driver behind the severe sell-off, overshadowing other market movements for the day. The dual events highlight ongoing volatility and regulatory scrutiny within the healthcare and pharmaceutical industries.